Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · QuidelOrtho (QDEL)

QuidelOrtho Q1 revenue falls 10.5% to $619.8 million; cuts 2026 guidance

Negative Impact 4 of 5 guidance Written later

QuidelOrtho reported first-quarter 2026 revenue of $619.8 million, down from $692.8 million a year earlier, and a GAAP net loss of $91.8 million, or $1.35 per share. The company cut its full-year 2026 guidance for revenue, adjusted EBITDA, adjusted diluted earnings per share and free cash flow, citing a weaker respiratory season and China and Middle East disruptions.

Key points

  • Q1 2026 total revenue was $619.8 million, down 10.5% from $692.8 million; Point of Care revenue fell 34.0% to $112.8 million.
  • GAAP net loss was $91.8 million, or $1.35 per diluted share, compared with a net loss of $12.7 million, or $0.19 per share, a year earlier.
  • Adjusted diluted loss per share was $0.04, compared with adjusted diluted earnings of $0.74 in the prior-year quarter.
  • 2026 guidance now calls for adjusted EBITDA of $615 million to $630 million (previously $630 million to $670 million) and adjusted diluted EPS of $1.80 to $2.00 (previously $2.00 to $2.42).

The filing

CompanyQuidelOrtho (QDEL)
Form8-K, current report
Filed with the SECMay 5, 2026, 4:07 PM ET
Accession number0001906324-26-000023

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.